Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

H. van Cruijsen; E.E. Voest; C.J.A. Punt; K. Hoekman; P.O. Witteveen; M.R. Meijerink; T.A. Puchalski; J. Robertson; O. Saunders; J.M. Jurgensmeier; C.M.L. van Herpen; G. Giaccone

doi:10.1016/j.ejca.2009.12.023

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

H. van Cruijsen, E.E. Voest, C.J.A. Punt, K. Hoekman, P.O. Witteveen, M.R. Meijerink, T.A. Puchalski, J. Robertson, O. Saunders, J.M. Jurgensmeier, C.M.L. van Herpen, G. Giaccone

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	901-911
Journal	European Journal of Cancer
Volume	46
Issue number	5
DOIs	https://doi.org/10.1016/j.ejca.2009.12.023
Publication status	Published - 2010

Access to Document

10.1016/j.ejca.2009.12.023

Cite this

van Cruijsen, H., Voest, E. E., Punt, C. J. A., Hoekman, K., Witteveen, P. O., Meijerink, M. R., Puchalski, T. A., Robertson, J., Saunders, O., Jurgensmeier, J. M., van Herpen, C. M. L., & Giaccone, G. (2010). Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. European Journal of Cancer, 46(5), 901-911. https://doi.org/10.1016/j.ejca.2009.12.023

van Cruijsen, H. ; Voest, E.E. ; Punt, C.J.A. ; Hoekman, K. ; Witteveen, P.O. ; Meijerink, M.R. ; Puchalski, T.A. ; Robertson, J. ; Saunders, O. ; Jurgensmeier, J.M. ; van Herpen, C.M.L. ; Giaccone, G. / Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. In: European Journal of Cancer. 2010 ; Vol. 46, No. 5. pp. 901-911.

@article{3781807fac544f4cad95ba5f4dbad1e4,

title = "Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours",

author = "{van Cruijsen}, H. and E.E. Voest and C.J.A. Punt and K. Hoekman and P.O. Witteveen and M.R. Meijerink and T.A. Puchalski and J. Robertson and O. Saunders and J.M. Jurgensmeier and {van Herpen}, C.M.L. and G. Giaccone",

year = "2010",

doi = "10.1016/j.ejca.2009.12.023",

language = "Undefined/Unknown",

volume = "46",

pages = "901--911",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Pergamon",

number = "5",

}

van Cruijsen, H, Voest, EE, Punt, CJA, Hoekman, K, Witteveen, PO, Meijerink, MR, Puchalski, TA, Robertson, J, Saunders, O, Jurgensmeier, JM, van Herpen, CML & Giaccone, G 2010, 'Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours', European Journal of Cancer, vol. 46, no. 5, pp. 901-911. https://doi.org/10.1016/j.ejca.2009.12.023

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. / van Cruijsen, H.; Voest, E.E.; Punt, C.J.A.; Hoekman, K.; Witteveen, P.O.; Meijerink, M.R.; Puchalski, T.A.; Robertson, J.; Saunders, O.; Jurgensmeier, J.M.; van Herpen, C.M.L.; Giaccone, G.

In: European Journal of Cancer, Vol. 46, No. 5, 2010, p. 901-911.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

AU - van Cruijsen, H.

AU - Voest, E.E.

AU - Punt, C.J.A.

AU - Hoekman, K.

AU - Witteveen, P.O.

AU - Meijerink, M.R.

AU - Puchalski, T.A.

AU - Robertson, J.

AU - Saunders, O.

AU - Jurgensmeier, J.M.

AU - van Herpen, C.M.L.

AU - Giaccone, G.

PY - 2010

Y1 - 2010

U2 - 10.1016/j.ejca.2009.12.023

DO - 10.1016/j.ejca.2009.12.023

M3 - Article

C2 - 20061136

VL - 46

SP - 901

EP - 911

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 5

ER -